Litcius/Paper detail

Targeting adipocyte differentiation with CRT0066101: activation of AMPK signaling in 3T3-L1 cells

Jinque Luo, Ling Wang, Li Zhang, Wenyu Tang, Meijing Deng, Yuxin Shi, Kun Xu, Qingjun Wu, Jie Zhao, Jing Zhang, Xin Li

2025Frontiers in Pharmacology8 citationsDOIOpen Access PDF

Abstract

Introduction: Obesity is characterized by excessive fat accumulation resulting from adipocyte hypertrophy and hyperplasia, with adipocyte differentiation being a central process driving these changes. Methods: The anti-adipogenic effects of CRT0066101 (CRT), a pan-protein kinase D (PKD) inhibitor, were evaluated in 3T3-L1 adipocytes. Potential drug targets of CRT were predicted using network pharmacology analysis. The expression of adipocyte-specific genes and proteins was assessed by western blotting and qRT-PCR. To examine the involvement of the AMPK pathway, cells were co-treated with CRT and the AMPK inhibitor Compound C. Results: CRT significantly inhibited early-stage adipocyte differentiation, reduced lipid accumulation, and downregulated key adipogenic transcription factors, including PPARγ and C/EBPα. Mechanistically, CRT activated the AMPK pathway, a known negative regulator of adipocyte differentiation. Network pharmacology analysis further supported the involvement of AMPK in CRT's anti-adipogenic action. Discussion: These findings identify CRT as a novel modulator of adipocyte differentiation through AMPK activation and highlight its potential as a therapeutic candidate for obesity and metabolic syndrome.

Topics & Concepts

AMPKAdipocyte3T3-L1Cell biologySignal transductionAdipogenesisChemistryBiologyAdipose tissueBiochemistryPhosphorylationProtein kinase AMesenchymal stem cellMetabolism, Diabetes, and CancerAdipokines, Inflammation, and Metabolic DiseasesPeroxisome Proliferator-Activated Receptors
Targeting adipocyte differentiation with CRT0066101: activation of AMPK signaling in 3T3-L1 cells | Litcius